Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis

Company Overview

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: N/A
• 50-Day Range: $9.47 to $13.76
• 52-Week Range: N/A
• Volume: 43,300 shs
• Average Volume: 95,409 shs
• Market Capitalization: $48.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AGLE Stock Analysis - Frequently Asked Questions

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($7.75) earnings per share for the quarter, missing the consensus estimate of ($7.00) by $0.75. The biotechnology company had revenue of $1.40 million for the quarter, compared to analysts' expectations of $1.38 million. Aeglea BioTherapeutics had a negative trailing twelve-month return on equity of 132.05% and a negative net margin of 22,195.36%.

When did Aeglea BioTherapeutics' stock split?

Aeglea BioTherapeutics shares reverse split before market open on Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Aeglea BioTherapeutics IPO?

Aeglea BioTherapeutics (AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What other stocks do shareholders of Aeglea BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aeglea BioTherapeutics investors own include Bristol-Myers Squibb (BMY), Athenex (ATNX), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD), Amarin (AMRN), Axsome Therapeutics (AXSM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AGLE
• CIK: 1636282
• Web: www.aegleabio.com
• Phone: (512) 942-2935
• Fax: 512-872-5121
• Employees: 69
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($75.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-83,820,000.00
• Net Margins: -22,195.36%
• Pretax Margin: -27,931.12%
• Return on Equity: -132.05%
• Return on Assets: -146.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.59

Sales & Book Value

• Annual Sales: $2.33 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($60.61) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,050,000
• Free Float: 3,782,000
• Market Cap: $48.64 million
• Optionable: Optionable
• Beta: 2.57